Adverse Drug Reaction Classification System

         

ADR Ontology
ADR Term Inflammation
ADR ID BADD_A05823
ADR Hierarchy
08      General disorders and administration site conditions
08.01      General system disorders NEC
08.01.05      Inflammations
08.01.05.007      Inflammation
10      Immune system disorders
10.02      Immune disorders NEC
10.02.01      Immune and associated conditions NEC
10.02.01.089      Inflammation
Description A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. [MeSH]
MedDRA Code 10061218
MeSH ID D007249
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE) Not Available
Synonym
Inflammation localised | Inflammation localized | Inflammation NOS | Inflammatory reaction | Inflammatory swelling | Inflammation | Exudative inflammation | Type 2 inflammation | Inflammatory infiltration | Inflammations
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D02407Upadacitinib0.001881%
BADD_D02412Octreotide0.000466%
BADD_D02423Fondaparinux0.004934%
BADD_D02450Crisaborole0.004008%
BADD_D02452Icatibant-
BADD_D02464Fingolimod0.005594%
BADD_D02470Nintedanib0.000336%
BADD_D02473Sodium chloride0.000362%
BADD_D02483Ribociclib0.000168%
BADD_D02487Baricitinib0.001061%
BADD_D02492Deflazacort0.000117%
BADD_D02498Abemaciclib0.000437%
BADD_D02504Lorlatinib0.000302%
BADD_D02511Siponimod--
BADD_D02539Calcium0.000391%
BADD_D02558Gadolinium cation (3+)-
BADD_D02567Lutetium lu-177 vipivotide tetraxetan-
BADD_D02568Lutetium oxodotreotide lu-177-
BADD_D02591Ripretinib0.000246%
BADD_D02597Tapinarof-
BADD_D02634Rolitetracycline--
BADD_D02635Rupatadine--
BADD_D02641Xylometazoline--
The 11th Page    First    Pre   11    Total 11 Pages
ADReCS-Target
ADR Term Drug Name Target